The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer.
 
Ron Bose
Honoraria - Genentech; Novartis
Consulting or Advisory Role - Genentech/Roche
 
Siraj Ali
No Relationships to Disclose
 
Naveen Jain
No Relationships to Disclose
 
Kyle Gowen
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Andrea Bertotti
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - University of Torino and Johns Hopkins University (Inst)
 
Elisa Murray
No Relationships to Disclose
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Research Funding - Foundation Medicine
 
Mary Stanley Beattie
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; Regeneron; Sanofi; TRACON Pharma
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); TRACON Pharma (Inst)
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)